OBLIQUE THERAPEUTICS AB

OBT develops medicines for advanced and metastatic cancers. We have a preclinical portfolio of small molecule and biologics programs, comprising an antibody-development platform for functional antibodies and a novel class of metabolic cytotoxics with immunomodulatory potential.